ICONIC-LEAD: 1 Year Icotrokinra Data Confirm Durable Psoriasis Clearance, PRO Improvements in Adults, Adolescents, With Jennifer Soung, MD

One-year data from the phase 3 ICONIC-LEAD trial confirm that icotrokinra (ICOTYDE) delivers durable skin clearance and meaningful patient-reported improvements across adults and adolescents with moderate-to-severe plaque psoriasis with no new safety signals through week 52.

Icotrokinra is the first and only targeted oral peptide blocking the IL-23 receptor after being approved by the United States Food and Drug Administration (FDA) on March 18, 2026 for moderate-to-severe plaque PsO in adults and adolescents 12 and older.

To discuss the findings presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 held in Denver, Colorado, from March 27-31, 

 spoke with Jennifer Soung, MD, Founder and Director of Clinical Research at Southern California Dermatology in Santa Ana, California, and ICONIC-LEAD investigator. ICONIC-LEAD enrolled 684 patients ≥12 years (adults, n = 618; adolescents, n = 66) with moderate-to-severe plaque PsO (BSA ≥10%, PASI ≥12, IGA ≥3). In the adult randomized-withdrawal analysis, of 341 week-24 responders re-randomized 1:1 to continue icotrokinra or withdraw to placebo, continuous icotrokinra produced superior maintenance of PASI 75 (89% vs. 30%; 

 <.001) at week 52, with median time to loss of response not reached in those continuing therapy versus 16.9 and 10.1 weeks for PASI 75 and PASI 90, respectively, among those re-randomized to placebo.

The adolescent data, presented across 2 companion posters at AAD, were particularly notable given the absence of approved advanced oral options for this population. Among adolescents randomized to icotrokinra (n = 44; mean age 15.0 years, mean PASI 19.8, 70% moderate/30% severe), 91% achieved IGA 0/1 and 86% achieved PASI 90 by week 52, with 89% of week-24 IGA 0/1 responders and 92% of week-24 PASI 90 responders maintaining those responses at week 52. Complete skin clearance rates were also substantial, with 64% achieving IGA 0 and 57% achieving PASI 100 during weeks 24–52. On patient-reported outcomes, more than 80% of icotrokinra-randomized adolescents reported clinically meaningful itch improvement (≥4-point PSSD improvement) through weeks 24–52, more than 50% reported complete symptom resolution (PSSD symptom score 0), approximately 40% reported complete sign resolution (PSSD sign score 0), and more than 80% reported psoriasis no longer impacted their health-related quality of life (CDLQI 0/1) — with improvements observed as early as week 2. Through week 52, no adolescent discontinued due to an adverse event, no serious infections occurred, and no malignancies were reported, with the overall safety profile consistent with the placebo-controlled period.

“This is the first time an advanced systemic has concurrently received approval for adults and adolescents at the same time, and that's a game changer, because our adolescent patients don’t really want an injection,” Soung said. “We also saw such amazing skin clearance rates in our adolescent patients. So I think that, again, making PsO treatment more accessible and easier for our patients means more of our patients will benefit from these treatments.”

Soung’s reported disclosures include AbbVie, Amgen, Arcutis, Aslan, Bristol Myers Squibb, Coval Biopharma, Dermavant, Eli Lilly, Johnson & Johnson, KoBio Labs, National Psoriasis Foundation, Novartis, Ortho Dermatologic, Oruka, Pfizer, Regeneron/Sanofi, and UCB.

Soung J, Lebwohl MG, Hebert A, et al. Durability of icotrokinra (targeted oral peptide) effects in adolescents with moderate-to-severe plaque psoriasis: one-year results from the ICONIC-LEAD study. Poster presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Poster P73600.

Soung J, Lebwohl MG, Hebert A, et al. Early and durable improvements in patient-reported outcomes with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: one-year results from the ICONIC-LEAD study. Poster presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Poster P73603.

Johnson & Johnson. FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide. Press release. March 18, 2026. 

https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide

Videos

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Petter Bjornstad, MD, is executive director of the UW Medicine Diabetes Institute, professor of pediatrics and medicine, and the Raisbeck Endowed Chair of Diabetes Research at the University of Washington.

REMODEL: Mechanistic Insights Into Semaglutide in CKD, With Petter Bjornstad, MD

 has evolved rapidly in recent years, with therapies now demonstrating meaningful benefits across kidney, cardiovascular, and metabolic outcomes. While large outcome trials have established efficacy, the understanding of the underlying mechanisms behind these protective effects has been limited.

The emergence of mechanistic studies such as the REMODEL trial marks a pivotal step toward answering that question, offering a deeper, biology-driven understanding of treatment effects in CKD. At the World Congress of Nephrology (WCN) 2026 Meeting in Yokohama, Japan, Petter Bjornstad, MD, executive director of the UW Medicine Diabetes Institute, professor of pediatrics and medicine, and the Raisbeck Endowed Chair of Diabetes Research at the University of Washington, presented an overview of REMODEL, including its framework and key outcomes, during a High Impact Clinical Trial session.

The rapid rise of GLP-1 RAs, including semaglutide, has transformed their role from glucose-lowering agents into foundational therapies used across endocrinology, cardiology, and nephrology. Their demonstrated benefits in weight reduction, cardiovascular risk, and kidney outcomes have driven widespread adoption and growing interest in their systemic effects.

In this context, mechanistic studies are increasingly important, helping to clarify the biological pathways that may underlie these broad clinical benefits. Bjornstad notes REMODEL stands out as a first-of-its-kind phase 3 mechanistic trial that integrates advanced imaging, tissue analysis, and biomarker discovery within the rigorous framework of a registration study. He emphasizes that this design serves as a “blueprint” for future trials, demonstrating that complex mechanistic investigations incorporating multiparametric MRI, kidney biopsy, and molecular profiling can be successfully conducted at scale across global sites.

From a mechanistic standpoint, he explains that the findings point to a central role for microvascular and endothelial health. Using functional MRI, the study demonstrated reduced renal vascular resistance, suggesting improved blood flow within the kidney. These findings were reinforced by biopsy data, which revealed gene expression patterns consistent with healthier endothelial cell function and enhanced intercellular communication.

Bjornstad situates these findings within the broader evidence base established by outcome trials, noting that the mechanistic insights from REMODEL help contextualize why GLP-1 RAs confer both renal and cardiovascular protection. He highlights that endothelial cells are present throughout the body, and improvements in vascular health may underpin the systemic benefits observed with these therapies.

The study also revealed reductions in fat surrounding and within the kidney, alongside consistent signals of vascular improvement across imaging, histology, and biomarker analyses. He underscores that this multidimensional validation strengthens confidence in the findings and enhances clinicians’ ability to interpret clinical trial outcomes.

Despite these advances, Bjornstad cautions that much remains to be understood. Ongoing analyses aim to further define the role of GLP-1 receptor expression and refine understanding of treatment response and residual risk. He also points to the growing pipeline of mechanistic trials as an encouraging trend, emphasizing that such studies are essential not only for understanding therapeutic effects, but also for identifying why some patients continue to progress despite treatment.

Editors’ Note: Bjornstad reports relevant disclosures with AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli-Lilly, LG Chemistry, Sanofi, Novo Nordisk, and Horizon Pharma, and others.

Cherney DZI, Belmar N, Bjornstad P, et al. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025;40(11):2182-2192. doi:10.1093/ndt/gfaf114

Brooks A. FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease. HCPLive. January 28, 2026. Accessed March 28, 2026. 

https://www.hcplive.com/view/fda-approves-semaglutide-ozempic-type-2-diabetes-chronic-kidney-disease

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Chee Kay Cheung MBChB PhD, is a consultant nephrologist and honorary senior lecturer at the University of Leicester.

IgAN Risk, Proteinuria Targets, and KDIGO Updates, With Chee Kay Cheung, MBChB, PhD

The management of IgA nephropathy (IgAN) is undergoing a rapid transformation, driven by a wave of emerging therapies and a deeper understanding of disease progression.

Historically, treatment strategies were constrained by limited options and an imprecise ability to identify which patients were most at risk for kidney decline. The latest update from Kidney Disease: Improving Global Outcomes (KDIGO) reflects a significant shift that moves the field toward more nuanced risk stratification, lower treatment targets, and a growing emphasis on targeted and combination therapies.

 at the World Congress of Nephrology (WCN) Conference in Yokohama, Japan, Chee Kay Cheung, MBChB, PhD, a consultant nephrologist and honorary associate professor at the University of Leicester, noted that one of the most important gaps in prior guidance was the lack of clarity around high-risk patients, with earlier definitions relying heavily on persistent proteinuria despite renin-angiotensin system inhibition.

“Now we have very much an expanding treatment landscape with the development of new targeted therapies for IgA nephropathy… which has meant that the guidelines have had to be revised and continue to be revised to accommodate these exciting developments,” he said.

Risk assessment has also evolved. Cheung points to the IgAN prediction tool as a valuable resource for estimating short- to medium-term risk—up to 7 years—based on large patient cohorts. However, he emphasizes that this falls short of capturing the lifelong trajectory of a disease often diagnosed in patients in their 30s or 40s. As a result, he highlights the need for improved tools that can better predict long-term outcomes and guide therapeutic decision-making.

One of the most notable changes in the updated guidance is a shift in proteinuria targets. Drawing on data from international registries, Cheung notes that even patients with proteinuria between 0.5 and 1 gram per day face a meaningful risk of progression, with approximately 30% advancing to kidney failure within a decade. In response, the guidelines now advocate for reducing proteinuria as much as possible, ideally < 0.3 grams per day.

Cheung also underscores the guideline’s new framework, which categorizes therapies into those targeting upstream immune mechanisms and those addressing downstream consequences of kidney injury. Despite this progress, he stresses that evidence supporting combination approaches remains limited. Determining how best to combine or sequence therapies and ensuring access to these treatments represents a critical unmet need.

Looking ahead, Cheung describes an increasingly complex but promising therapeutic landscape. With additional agents entering clinical use and evolving guidance on their placement, he emphasizes that optimizing treatment strategies will be central to improving long-term outcomes for patients with IgAN.

“I think it's a very exciting time in IgA nephropathy, and there are more treatments coming. These all look very promising in terms of tolerability, in terms of efficacy, and where we place these treatments is going to be a key question in the future as well.”

include Travere Therapeutics, Alexion, Alpine Immune Sciences, Calliditas Therapeutics, CSL Vifor, Novartis, Otsuka Pharmaceutical, Roche, Vera Therapeutics, and others.

Brooks A. KDIGO Releases Updated IgA Nephropathy, IgA Vasculitis Clinical Practice Guideline. HCPLive. September 18, 2025. Accessed March 28, 2026. 

https://www.hcplive.com/view/kdigo-releases-updated-iga-nephropathy-iga-vasculitis-clinical-practice-guideline

KDIGO updates in IgA nephropathy highlight lower proteinuria targets, improved risk tools, and an expanding landscape of targeted and combination therapies.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Michelle Bichchau Nguyen, MD, MBA, MPH, is an associate professor of dermatology at Tufts University School of Medicine and the director of Mohs Micrographic Surgery.


What Are the Biggest Drivers of Dissatisfaction in Dermatology? With Michelle Nguyen, MD, MBA, MPH

In a second interview segment recorded at the 

 in Denver, Michelle Bichchau Nguyen, MD, MBA, MPH, associate professor of dermatology at Tufts University School of Medicine and director of Mohs Micrographic Surgery, spoke with 

 about her practical guidance on the most common drivers of patient dissatisfaction in dermatology.

Specifically, Nguyen went into what early-career clinicians can do in order to build more meaningful, lasting connections with their patients. When asked to identify the single biggest driver of dissatisfaction in dermatology practices, Nguyen pointed directly to the challenge of high patient volume and the toll it can take on the quality of each of these encounters.

“[Just] the fact that you're sitting down and having a conversation instantly make patients feel like…it's worth it to wait three months to see you and paying the co-pays and all of that,” Nguyen expressed.

In a specialty where clinicians are routinely required to interact with large numbers of patients in relatively short windows of time, Nguyen pointed out, it becomes can be all the more critical to be intentional about making each these individuals feel heard and valued. Nguyen also described the physical act of sitting during a patient conversation, rather than standing at the door or typing at a workstation, as immediately making the clinician appear present and engaged.

Additionally, Nguyen reframed the time investment in rapport-building as a long-term strategic asset, as opposed to only a courtesy. Concerns left unaddressed in a single visit, she explained, tend to compound over time. This can make future encounters more difficult and the therapeutic relationship more fragile. Dermatology clinicians who invest upfront in building trust, she expressed, ultimately benefit from greater patient loyalty.

Turning to advice for early-career dermatologists specifically, Nguyen further highlighted an important dimension to her earlier guidance on listening: do not take negative feedback personally. Nguyen noted critical patient reviews can sting for clinicians, especially those who are newer. Rather than internalizing those situations as reflections of their worth as clinicians, Nguyen encouraged residents and junior physicians to mine each piece of criticism for a kernel of actionable truth.

Nguyen had no relevant financial disclosures of note.

Nguyen M. Ways to Improve Patient Experience with Surgery in Dermatology, With Michelle Nguyen, MD, MBA, MPH. HCPLive. March 27, 2026. 

https://www.hcplive.com/view/ways-improve-patient-experience-surgery-dermatology-michelle-nguyen-md-mba-mph

Gahona M, Prada SA, Chaparro D. Patient satisfaction as a quality indicator in dermatological care: cross-sectional study in two tertiary institutions with residency programs. An Bras Dermatol. 2025 Nov-Dec;100(6):501228. 

. Epub 2025 Nov 3. PMID: 41187473; PMCID: PMC12634491.

This interview at AAD 2026 highlights Nguyen's views on the biggest drivers of patient dissatisfaction in dermatology practice settings.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

New 52-week data from a phase 3b trial of tildrakizumab (Sun Pharma, ILUMYA) in moderate-to-severe nail psoriasis, presented at the 

 held in Denver, Colorado, from March 27-31, show continued improvement in nail clearance and sustained response among early responders — extending results first reported at last year’s meeting.¹

The study (NCT03897075) is the first dedicated phase 3b trial of an IL-23 inhibitor in nail psoriasis, a manifestation affecting roughly 40–50% of patients with plaque psoriasis that remains among the most difficult-to-treat domains of the disease due to the slow growth rate of the nail plate and limited long-term clinical trial data.²

The multicenter, randomized, double-blind, placebo-controlled study enrolled 99 adults with moderate-to-severe plaque psoriasis and concurrent nail involvement, defined by a modified Nail Psoriasis Severity Index (mNAPSI) score of ≥20 and a ViSENPsO score of ≥3. Patients received tildrakizumab 100 mg or placebo; those originally randomized to placebo crossed over to tildrakizumab at week 28.¹

The primary endpoint of mNAPSI 75 response at week 28  was met, with 25.5% of tildrakizumab-treated patients achieving ≥75% improvement from baseline versus 4.5% in the placebo arm (

 = .003). Additionally, 29.4% of tildrakizumab-treated patients achieved a ViSENPsO score of 0 (normal) or 1 (minimal) with a ≥2-point decrease from baseline, compared to 4.2% with placebo (

Among 72 patients who completed the study through week 52, of which 40 were originally randomized to tildrakizumab and 32 originally to placebo, response rates in the continuous tildrakizumab arm continued to increase beyond week 28. The mNAPSI 75 response rate rose from 25.5% at week 28 to 41.2% at week 52, and 76.9% of week-28 mNAPSI 75 responders maintained that response at week 52.¹

A similar trajectory was observed for the ViSENPsO endpoint. The proportion achieving normal or near-normal nails increased from 29.4% at week 28 to 43.1% at week 52, with 60.0% of week-28 ViSENPsO responders sustaining that response at week 52.¹

The continued gains between weeks 28 and 52 are consistent with the biology of nail psoriasis treatment: fingernails take approximately 6 months to fully regenerate, meaning the full benefit of anti-inflammatory therapy on nail architecture emerges gradually and is often not captured at earlier timepoints.²

Investigator Paul Yamauchi, MD, PhD, President and Director of Dermatology, Dermatology Institute and Skin Care Center, and colleagues saw that safety through week 52 was consistent with tildrakizumab's established profile. Serious adverse events (AEs) occurred in 3 patients (5.9%) originally randomized to tildrakizumab. AEs of special interest were reported in 2 patients (3.9%) — 1 injection-related reaction and one case of pruritus. Missing data were imputed as nonresponse throughout.¹

Tildrakizumab selectively binds the p19 subunit of IL-23, suppressing downstream signaling through the Th17 axis that drives both cutaneous and nail manifestations of psoriasis. The drug is approved in the United States, Australia, Japan, and Europe (as ILUMETRI, marketed by Almirall) for moderate-to-severe plaque psoriasis. Sun Pharma also recently received Food and Drug Administration (FDA) acceptance of an sBLA for tildrakizumab in active PsA, with a PDUFA date of October 29, 2026, based on positive topline results from the INSPIRE-1 and INSPIRE-2 phase 3 trials.

Data from the AAD 2026 presentation represent the complete 52-week dataset for this nail psoriasis study. Full publication in a peer-reviewed journal is anticipated.

Yamauchi P, et al. Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: a multicenter, randomized, double-blind, placebo-controlled phase 3b trial. Presented at: 2026 AAD Annual Meeting; March 27–31, 2026; Denver, CO. Poster #72762

Renert-Yuval Y, Guttman-Yassky E, et al. Nail psoriasis: an updated review of currently available systemic treatments. 

Articles

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tildrakizumab Sustains Nail Psoriasis Efficacy Through 52 Weeks in Phase 3b Extension Data

This interview at AAD 2026 highlights tips for clinicians in dermatology practices who want to improve patient communication and satisfaction.

Ways to Improve Patient Experience with Surgery in Dermatology, With Michelle Nguyen, MD, MBA, MPH

Abdallah Geara, MD, is an Associate Professor of Clinical Medicine at the University of Pennsylvania.

Corey Cavanaugh, DO, and Abdallah Geara, MD, separately share their perspectives on the clinical clues for IgAN diagnosis, including hypertension and microscopic hematuria.

Strategic Alliance Partnership

2 IgA Nephropathy Experts Explain Clues For Early Intervention and Diagnosis

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These new data on spesolimab (Spevigo) in adults with generalized pustular psoriasis highlight long-term findings with the treatment.

EFFISAYIL ON: New Long-Term Data Released on Spesolimab Injection for GPP

Monica Kraft, MD, is Murray M. Rosenberg Professor of Medicine and System Chair for the Department of Medicine at Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai.

Deep learning applied to routine ECGs identified COPD up to 15 months earlier, supporting earlier intervention and risk stratification strategies.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

AI-ECG Model Detects COPD Months Before Diagnosis, With Monica Kraft, MD

Andres Gelrud, MD, is a gastroenterologist at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Diagnosing and Managing Exocrine Pancreatic Insufficiency, With Andres Gelrud, MD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

AstraZeneca's investigational IL-33–targeting antibody tozorakimab met its primary endpoint in both the phase III OBERON and TITANIA trials.

IL-33 Inhibitor Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials

The FDA has approved a labeling update for 1 mg epinephrine nasal spray  permitting use in any patient weighing 33 lbs or more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

FDA Removes Age Requirement for Epinephrine Nasal Spray, Now Based on Weight Alone

A post-hoc analysis of phase 3 trials found tapinarof cream 1%  produced skin clearance and itch relief as early as week 1 in patients aged 2 years and older.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Tapinarof Cream Clears Skin, Eases Itch Within 1 Week in Kids as Young as 2 Years

Shared decision-making around initiating targeted therapy, key safety considerations for avapritinib, and core efficacy and safety findings from the 6‑month randomized phase of the PIONEER trial.

Video Series

Targeted Therapy in ISM: Shared Decision-making, Safety, and Early PIONEER Data

Positive stool test? Learn why follow-up colonoscopy is often covered and how clinics tackle cost, time-off, and transport barriers.

Latest News

ICONIC-LEAD: 1 Year Icotrokinra Data Confirm Durable Psoriasis Clearance, PRO Improvements in Adults, Adolescents, With Jennifer Soung, MD

REMODEL: Mechanistic Insights Into Semaglutide in CKD, With Petter Bjornstad, MD

IgAN Risk, Proteinuria Targets, and KDIGO Updates, With Chee Kay Cheung, MBChB, PhD

What Are the Biggest Drivers of Dissatisfaction in Dermatology? With Michelle Nguyen, MD, MBA, MPH

Tildrakizumab Sustains Nail Psoriasis Efficacy Through 52 Weeks in Phase 3b Extension Data